We only have this paper's title and publication details.
Read it at the sourceAnswers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“This is a new, transformational technology for our patients; we have never had this type of an approach before; it's not like another balloon catheter. As this technology is introduced into practice, detailed and agreed upon protocols are needed to ensure we achieve optimal clinical results. This consensus document provides the field with clear recommendations and guidance for its use.”
“Our goal in crafting this expert consensus document is to provide a clear roadmap for the use of TAVR as it reaches patients across the United States. TAVR innovation is a major advance in treating aortic stenosis and sick, elderly patients should have access to this new treatment so they can resume normal, active lives. These guidelines are a coordinated effort from the cardiovascular community to help ensure the appropriate use of TAVR therapy for optimum patient safety.”
“This is tremendous news for Medicare beneficiaries. ACC is pleased that CMS is proposing a national coverage policy that balances the critical need to provide access to this important, innovative service with the need to ensure that care is provided in qualified facilities by highly skilled heart care teams and the need to collect data on experience with the device and procedure in the real world.”
No takes yet. Share an insight, caveat, or question.
Holmes et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: